Stay Ahead of Compliance with Monthly Citation Updates


In your State Survey window and need a snapshot of your risks?

Survey Preparedness Report

One Time Fee
$79
  • Last 12 months of citation data in one tailored report
  • Pinpoint the tags driving penalties in facilities like yours
  • Jump to regulations and pathways used by surveyors
  • Access to your report within 2 hours of purchase
  • Easily share it with your team - no registration needed
Get Your Report Now →

Monthly citation updates straight to your inbox for ongoing preparation?

Monthly Citation Reports

$18.90 per month
  • Latest citation updates delivered monthly to your email
  • Citations organized by compliance areas
  • Shared automatically with your team, by area
  • Customizable for your state(s) of interest
  • Direct links to CMS documentation relevant parts
Learn more →

Save Hours of Work with AI-Powered Plan of Correction Writer


One-Time Fee

$49 per Plan of Correction
Volume discounts available – save up to 20%
  • Quickly search for approved POC from other facilities
  • Instant access
  • Intuitive interface
  • No recurring fees
  • Save hours of work
F0756
D

Failure to Follow Up on Pharmacist's Anticoagulant Recommendation

Cherryvale, Kansas Survey Completed on 09-04-2025

Penalty

No penalty information released
tooltip icon
The penalty, as released by CMS, applies to the entire inspection this citation is part of, covering all citations and f-tags issued, not just this specific f-tag. For the complete original report, please refer to the 'Details' section.

Summary

The facility failed to acknowledge and/or act on the consultant pharmacist's recommendation regarding the use of an anticoagulant medication for a resident with a history of stroke, hypertension, chronic kidney disease, and moderate cognitive impairment. The pharmacist had identified that the resident was receiving Xarelto, which is listed in the 2019 Beers Criteria as having an increased risk of serious bleeding in adults over 75 years when used long-term. The pharmacist recommended considering discontinuation or replacement of Xarelto with Eliquis and sent this recommendation to the physician for follow-up. Despite this recommendation, there was no evidence in the clinical record that the facility obtained a response from the physician or followed up on the pharmacist's recommendation for over 42 days. The administrative nurse confirmed that the lack of follow-up was an oversight and the facility did not have a policy in place to address follow-up on consultant pharmacist recommendations. This inaction resulted in the resident continuing to receive the medication without documented physician review or response to the identified irregularity.

An unhandled error has occurred. Reload 🗙